Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial

Lakewood-Amedex Nu-3 Phase 2a Trial Cleared

Analysis based on 8 articles · First reported Sep 18, 2026 · Last updated Sep 24, 2026

Sentiment
5
Attention
1
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The news is a modest positive for Lakewood-Amedex as it de-risks near-term clinical progress on its lead asset, though the small-cap clinical-stage profile and absence of efficacy data limit broad market reaction. Sector impact is minimal, with attention confined to the antimicrobial and wound-care niche rather than the wider biotech or pharmaceutical complex.

biotechnology pharmaceuticals

Lakewood-Amedex Biotherapeutics Inc. announced that it has obtained central and all site Institutional Review Board (IRB) approvals and confirmed clinical trial site readiness to commence its Phase 2a clinical trial of its lead product candidate Nu-3 in patients with mildly infected diabetic foot ulcers (iDFU). Nu-3 is a proprietary topical gel from the company's Bisphosphocin class of fast-acting, broad-spectrum antimicrobials that destabilizes microbial cell membranes, offering a high barrier to antimicrobial resistance. The trial builds on positive preclinical safety data and early exploratory results showing Nu-3 was well-tolerated with trends of improved antimicrobial response and wound healing. Chief Medical Officer Thomas Balzer called the milestones a significant step forward in addressing drug-resistant wound infections, and noted the guidance of Study Chair David G. Armstrong. The company framed the effort as aligned with federal mandates from the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB). The announcement was distributed via multiple press release channels and the company was also highlighted as a new B2i Digital Featured Company. No trial start date, enrollment figures, or financial terms were disclosed.

80 Lakewood-Amedex Biotherapeutics Inc. obtained IRB approvals
priv
The company is the sole actor in this event, securing IRB approvals and site readiness for the Phase 2a Nu-3 trial in infected diabetic foot ulcers. The milestone advances its lead Bisphosphocin candidate and modestly improves its clinical and financing narrative.
Importance 100.0 Sentiment 25.0
per
Armstrong is named as Study Chair for the Nu-3 Phase 2a trial, lending clinical credibility to the program. His role is advisory and carries no direct financial exposure.
Importance 20.0 Sentiment 5.0
per
Balzer, as Chief Medical Officer, publicly framed the IRB approval and site readiness as a significant development step. His statements support the company's positioning but do not independently move markets.
Importance 20.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.